Relay Therapeutics said on Monday interim data from an early-stage study of its combination drug for breast cancer showed it ...

The combo will compete with AstraZeneca’s Tagrisso ... FDA allows BioNTech-MediLink ADC trial to resume with lower, safer doses After a safety scare in mid-June, the FDA has allowed MediLink ...

Brandywine Cares is announcing the launch of CareerProsper 3.0., a six-week program designed to empower individuals with skills, knowledge, and financial acuity needed to advance their careers into ...

AstraZeneca’s Imfinzi recently became the first PD-1/L1 inhibitor to deliver a patient survival win in muscle-invasive ...

A Phase 3 trial found AstraZeneca's experimental lung cancer drug datopotamab deruxtecan did not significantly improve patients' overall survival rates. The results from the trial showed that the ...

Recently, Chinese authorities detained some current and former employees of AstraZeneca Plc (NASDAQ ... The share move following the trial result doesn’t take account of the overall strength ...

AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared ...

The TROPION-Lung01 Phase III trial evaluated AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan compared to docetaxel, the current standard of care chemotherapy, in adult patients with ...

A Phase 3 trial found AstraZeneca's experimental lung cancer drug did not significantly improve patients' overall survival rates.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's datopotamab deruxtecan (Dato-DXd) has shown a trend toward improving overall survival (OS) compared with chemotherapy in a Phase III trial for certain ...